Skip to main content

Clinical Trials Using Trastuzumab

Review the clinical trials studying trastuzumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-48 of 48

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Status: Active
Location: 3 locations
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Status: Active
Location: 3 locations
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Status: Active
Location: 3 locations
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
Status: Active
Location: 3 locations
Early Clinical Response Correlation to Pathologic Outcome for Treatment in Patients with Invasive Breast Cancer Undergoing Chemotherapy Before Surgery
Status: Active
Location: 2 locations
Radiation Therapy Followed by Trastuzumab and Pertuzumab for the Treatment of HER2 Positive Breast Cancer that has Spread to the Leptomeninges
Status: Active
Location: 2 locations
Emavusertib in Combination with Combination Chemotherapy and Immunotherapy with or without Trastuzumab for the Treatment of Advanced Unresectable or Metastatic Gastric or Esophageal Cancer
Status: Active
Location: 2 locations
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Status: Active
Location: 2 locations
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Reduced Adjuvant Systemic Therapy for the Treatment of Patients with Early Breast Cancer Who Experienced a Pathological Complete Response After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease, MolecularPCR Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy before Surgery for the Treatment of Patients with Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Trastuzumab, Pertuzumab and Docetaxel With or Without Carboplatin for the Treatment of Stage II-III HER2 Positive Breast Cancer, NeoTHERa Trial
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
A Vaccine (Dendritic Cell 1) for the Treatment of Patients with HER-2 Positive Breast Cancer, NATASHA Study
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Neratinib in Combination with Chemotherapy, Trastuzumab, Pembrolizumab in Patients with Stage HER2 Overexpressing Stage IV Gastroesophageal Cancers
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Adoptive T-Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine, Pepinemab and Trastuzumab for the Treatment of HER2 Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Status: Active
Location: See ClinicalTrials.gov
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of gFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients with HER2 Low and HER2+ Breast Cancer with Brain Metastasis
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California